US Patent

US11850223 — Methods of treatment of cholestatic diseases

Method of Use · Assigned to Genfit SA · Expires 2037-03-30 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of Elafibranor for treating cholestatic diseases, specifically Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC).

USPTO Abstract

The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.

Drugs covered by this patent

Iqirvo (ELAFIBRANOR) · Ipsen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1854`	—	Iqirvo

Patent Metadata

Patent number: US11850223
Jurisdiction: US
Classification: Method of Use
Expires: 2037-03-30
Drug substance claim: No
Drug product claim: No
Assignee: Genfit SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.